|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0008976,
umls-concept:C0022341,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0282460,
umls-concept:C0762659,
umls-concept:C1274040,
umls-concept:C1515417,
umls-concept:C1518578,
umls-concept:C1705493
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-25
|
|
pubmed:abstractText |
Amrubicin is a synthetic anthracycline drug that is a potent inhibitor of topoisomerase II. We have performed a multicenter phase II trial to evaluate the efficacy and safety of amrubicin for patients with previously treated non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:AkitaKenjiK,
pubmed-author:FukuokaMasahiroM,
pubmed-author:GotoIsaoI,
pubmed-author:HayashiHidetoshiH,
pubmed-author:IwamotoYasuoY,
pubmed-author:KanedaHiroyasuH,
pubmed-author:KimuraTatsuoT,
pubmed-author:KudohShinzohS,
pubmed-author:MiyazakiMasakiM,
pubmed-author:NakagawaKazuhikoK,
pubmed-author:OkamotoIsamuI,
pubmed-author:SaitoHiroshiH,
pubmed-author:SatouchiMiyakoM,
pubmed-author:SawaToshiyukiT,
pubmed-author:ShibataKazuhikoK,
pubmed-author:SugiuraTakamuneT,
pubmed-author:TakedaKojiK,
pubmed-author:West Japan Thoracic Oncology Group,
pubmed-author:YoshiokaHiroshigeH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
105-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19884859-Adenocarcinoma,
pubmed-meshheading:19884859-Aged,
pubmed-meshheading:19884859-Anthracyclines,
pubmed-meshheading:19884859-Antineoplastic Agents,
pubmed-meshheading:19884859-Carcinoma, Large Cell,
pubmed-meshheading:19884859-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19884859-Carcinoma, Squamous Cell,
pubmed-meshheading:19884859-Female,
pubmed-meshheading:19884859-Follow-Up Studies,
pubmed-meshheading:19884859-Humans,
pubmed-meshheading:19884859-Japan,
pubmed-meshheading:19884859-Lung Neoplasms,
pubmed-meshheading:19884859-Male,
pubmed-meshheading:19884859-Middle Aged,
pubmed-meshheading:19884859-Neoplasm Recurrence, Local,
pubmed-meshheading:19884859-Neoplasm Staging,
pubmed-meshheading:19884859-Prognosis,
pubmed-meshheading:19884859-Salvage Therapy,
pubmed-meshheading:19884859-Survival Rate,
pubmed-meshheading:19884859-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
|
|
pubmed:affiliation |
Department of Medical Oncology, Kinki University School of Medicine, Osaka-sayama, Osaka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
